Ono and EVQLV partner to develop new antibody drugs
Pharmaceutical Technology
DECEMBER 22, 2023
Ono has signed an agreement with EVQLV to utilise its AI-powered antibody design engine for the development of new antibody drugs.
This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.
Pharmaceutical Technology
DECEMBER 22, 2023
Ono has signed an agreement with EVQLV to utilise its AI-powered antibody design engine for the development of new antibody drugs.
Pharmaceutical Technology
APRIL 9, 2024
The grant will support the preclinical development of the antibody acquired by Basilea from Spexis in January.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
OCTOBER 12, 2023
Almirall will license EpimAb’s Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform to develop up to three bispecific antibody targets.
Pharmaceutical Technology
OCTOBER 17, 2023
LegoChem Biosciences has entered an exclusive worldwide licensing agreement with Glycotope to develop an antibody-drug conjugate (ADC).
Pharmaceutical Technology
OCTOBER 10, 2023
The companies will develop multiple monoclonal antibodies against membrane proteins, such as GPCRs and SLC transporters.
Pharmaceutical Technology
OCTOBER 5, 2023
IMIDomics and WuXi Biologics have signed an agreement to advance the development and manufacturing of the humanised antibody, IMB1001
Pharmaceutical Technology
SEPTEMBER 14, 2023
AbCellera and Incyte have entered a partnership for the discovery and development of therapeutic antibodies in oncology.
Pharmaceutical Technology
SEPTEMBER 28, 2023
Ono Pharmaceutical and Adimab have signed a drug discovery collaboration agreement for the development of antibody drugs in oncology
Pharmaceutical Technology
JULY 3, 2023
Chime Biologics, Leads Biolabs and BeiGene have entered a strategic partnership to expedite the development of a monoclonal antibody, LBL-007.
Pharmaceutical Technology
SEPTEMBER 1, 2023
Twist and Ono will discover and develop novel antibodies to treat autoimmune diseases and generate comprehensive discovery campaigns.
Pharmaceutical Technology
JULY 12, 2023
Crossbow Therapeutics has raised Series A funds worth $80m to develop a new class of antibody treatments for cancer.
Pharmaceutical Technology
AUGUST 29, 2022
Sanyou Biopharmaceuticals and Shanghai KangaBio have signed a licencing agreement to expedite the development and innovation of the former’s monoclonal antibody drug. Sanyou and KangaBio will join forces to offer new prodrug development for immunotherapy based on their expertise and industry resources.
Pharmaceutical Technology
SEPTEMBER 22, 2022
Abpro has entered a strategic collaboration with Celltrion for the global development and commercialisation of the former's antibody therapy, a t-cell engager known as ABP 102. The cancer molecule will be developed for treating patients with HER2+ cancer, including gastric, pancreatic and breast cancer.
Pharmaceutical Technology
JULY 25, 2024
Dren Bio has entered a strategic partnership with Novartis Pharma to develop therapeutic bispecific antibodies to treat cancer.
Bio Pharma Dive
MAY 7, 2024
The $200 million round is the latest evidence that surging interest in autoimmune disease cell therapies could expand to include developers of bispecific antibodies, too.
Pharmaceutical Technology
MARCH 16, 2023
Talem Therapeutics, a subsidiary of Immunoprecise Antibodies, has entered a multi-target artificial intelligence (AI)-driven antibody discovery collaboration with Libera Bio. The MPN Technology provides an elegant way for delivering antibodies inside tumour cells.
Pharmaceutical Technology
DECEMBER 26, 2022
LegoChem Biosciences and Amgen have signed a multi-target research collaboration and license agreement to develop antibody-drug conjugates (ADC). As per the terms of the agreement, LegoChem will receive up to $1.25bn in upfront, development and commercial milestone payments from Amgen.
Pharmaceutical Technology
OCTOBER 12, 2022
Biotech start-up Toregem BioPharma has signed a memorandum of understanding (MoU) with WuXi Biologics to develop the monoclonal antibody, TRG035. Under the MoU, the companies will form a collaboration for the development of TRG035, which targets USAG-1 to treat congenital adentia.
Pharmaceutical Technology
MAY 2, 2024
Discover how Agenus Inc's groundbreaking patent for antibodies targeting TIM-3 is revolutionizing therapeutic antibody development. Explore the specific amino acid sequences and methods for efficient antibody production.
Pharmaceutical Technology
OCTOBER 20, 2023
The company plans to initiate the Phase II trial of anti-IL-6 antibody in atherosclerotic cardiovascular disease in 2024.
Pharmaceutical Technology
NOVEMBER 16, 2022
Clinical-stage biopharmaceutical companies NextCure and LegoChem Biosciences have signed a collaboration and co-development agreement to develop a B7-H4 antibody drug conjugate (ADC), and features options for two further targets. Furthermore, NextCure signed a supply agreement for Keytruda with Merck.
Pharmaceutical Technology
FEBRUARY 15, 2023
In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology: Leading companies in cancer monoclonal antibody therapy. Immatics is one of the most important players concerning innovation surrounding cancer monoclonal antibody therapy.
Drug Discovery World
APRIL 22, 2024
Join DDW for this free event ‘ Where is the opportunity in the therapeutic antibody market? ’, which is co-sponsored by Bio-Rad and Benchling. Dr Milind Nigam will discuss the role of software in accelerating the pace of discovery of antibody therapeutics. What effect has antibody engineering had on drug discovery and development?
BioPharma Reporter
JULY 30, 2024
Eager to tap into a high-growth market, Novartis has sealed a pact worth up to $3 billion with Dren Bio to co-develop antibody treatments for cancer.
BioPharma Reporter
JULY 30, 2024
Eager to tap into a high-growth market, Novartis has sealed a pact worth up to $3 billion with Dren Bio to co-develop antibody treatments for cancer.
Pharmaceutical Technology
OCTOBER 21, 2022
AbbVie has announced the acquisition of UK-based biotechnology firm DJS Antibodies for nearly $255m in cash at closing. DJS focuses on the discovery and development of antibody therapies that act on difficult-to-drug disease-causing proteins, such as G protein-coupled receptors (GPCRs).
Pharmaceutical Technology
DECEMBER 15, 2023
Teva Pharmaceutical has signed a licence agreement with Biolojic Design for the development of BD9 to treat atopic dermatitis and asthma.
Bio Pharma Dive
MAY 16, 2024
The deal is part of a plan by J&J to build a portfolio of “differentiated” bispecific antibodies, an increasingly popular area of drug development.
Pharmaceutical Technology
FEBRUARY 15, 2024
Ono Pharmaceutical has entered an agreement with Numab Therapeutics for developing and commercialising NM49 in the oncology field.
Drug Discovery World
MAY 21, 2024
Ben Holland , CTO and Co-Founder of Antiverse discusses how artificial intelligence and machine learning are benefitting antibody discovery and design. Modern experimental procedures, such as immunisation, B-cell screening, and synthetic library generation, have been pivotal in developing approximately 80 FDA-approved antibody therapeutics.
Pharmaceutical Technology
JUNE 11, 2024
Adcytherix has announced its launch with seed funding of €30m ($32.2m) to develop antibody-drug conjugates (ADCs) for cancer treatment.
Pharmaceutical Technology
FEBRUARY 22, 2024
Ono Pharmaceutical has partnered with EME to advance the drug discovery of VHH antibodies to develop new therapeutic agents.
Pharmaceutical Technology
JULY 21, 2022
AstraZeneca has signed a deal with the Federal Office of Public Health (FOPH) of Switzerland to deliver over 1,200 doses of antibody therapy, tixagevimab and cilgavimab combination (AZD7442), for Covid-19 prevention and treatment. In May, the company supplied the first doses of the antibody therapy to Swiss hospitals for Covid-19 prevention.
Pharmaceutical Technology
JULY 4, 2022
Brii Biosciences (Brii Bio) has exercised an option for the acquisition of exclusive development and marketing rights for Vir Biotechnology’s investigational antibody, VIR-3434, for Hepatitis B in Greater China, under a partnership agreement. The mAb is presently in the Phase II development stage.
Bio Pharma Dive
APRIL 19, 2021
Adagio Therapeutics, a well-financed spinout of antibody developer Adimab, could challenge Regeneron and Eli Lilly if its drug candidate proves protective in clinical tests.
Pharmaceutical Technology
SEPTEMBER 6, 2023
Zenas BioPharma and BMS have signed an agreement for the development and commercialisation of obexelimab to treat autoimmune ailments.
Pharmaceutical Technology
MAY 24, 2023
HBM’s wholly owned subsidiary Nona Biosciences has entered an agreement with OPKO Health’s ModeX Therapeutics for the discovery of antibodies. ModeX Therapeutics will gain access to the fully human Harbour Mice platforms of Nona Bioscience for integration into its MSTAR platform to expedite the monoclonal antibodies’ discovery.
Pharmaceutical Technology
OCTOBER 26, 2023
The Series A funds will go towards the clinical development of TRIV-509, with plans for a proof-of-concept atopic dermatitis study.
Pharmaceutical Technology
DECEMBER 4, 2023
The $247m deal will focus on the use of generative artificial intelligence to develop an antibody therapy for an unnamed cancer.
Pharmaceutical Technology
JANUARY 9, 2023
Eisai and Biogen have received approval for their antibody Leqembi (lecanemab-irmb) , 100mg/mL injection for intravenous use, from the US Food and Drug Administration (FDA) under the Accelerated Approval Pathway to treat Alzheimer’s disease (AD). The regulatory approval is based on the data obtained from the Phase II trial.
Bio Pharma Dive
JULY 28, 2021
The acquisition is the third Amgen has made since March and broadens its ability to develop bispecific antibodies, a drug class of intense interest to big biotech.
Pharmaceutical Technology
JANUARY 23, 2024
Calluna has four monoclonal antibody candidates in the pipeline under development for inflammatory and fibrotic diseases.
Pharmaceutical Technology
NOVEMBER 22, 2023
Myricx Bio has signed a licence agreement for contract research, development and manufacturing organisation WuXi Biologics’ antibody.
Pharmaceutical Technology
JULY 6, 2023
F-star Therapeutics and Takeda have signed a strategic discovery partnership and licence deal to develop multi-specific immunotherapies.
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content